Voyager Therapeutics (VYGR) Proxy filing summary

Executive summary

• Annual meeting scheduled for June 9, 2026, at 9:00 AM ET, to be held virtually for shareholder participation.

• Shareholders are encouraged to review proxy materials online or request copies before voting.

Voting matters and shareholder proposals

• Election of three Class II director nominees to serve until the 2029 annual meeting: James A. Geraghty, Steven Hyman, M.D., and Alfred Sandrock, M.D., Ph.D.

• Advisory vote to approve named executive officer compensation.

• Ratification of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2026.

• Proposal to amend the certificate of incorporation to increase authorized capital stock from 125,000,000 to 245,000,000 shares and common stock from 120,000,000 to 240,000,000 shares.

• Board may transact other business as may properly come before the meeting.

Board of directors and corporate governance

• Board recommends voting in favor of all proposals, including director elections and amendments.